Answers are grounded in this paper and cite their sources.
During 2017-2025, Taiwan had made substantial progress toward HCV elimination with achievement of 92.6% direct-acting antiviral coverage. In this setting, monitoring the residual transmissions of HCV among high-risk populations become essential. Therefore, we conducted this cohort study to evaluate the temporal trends in HCV infection among people with HIV (PWH). PWH who regularly sought HIV care at the National Taiwan University Hospital were included for periodical HCV antibody screening, and HCV-seropositive PWH underwent HCV RNA testing. PWH who cleared HCV viremia, by treatment or spontaneously, were followed using HCV RNA tests to detect reinfections. The prevalence and incidence of HCV viremia and incidence of reinfection were calculated yearly from 2019-2025. The estimates in 2025 were compared to the peak estimates of the cohort. Overall, 3,637 PWH, with a median age of 40.4 years and 81.4% being men who have sex with men, were included in the study. Compared to 2019, the prevalence of HCV viremia decreased from 4.4% to 0.9% in 2025, representing a 78.7% reduction (95% CI, 66.9%-86.2%); and the incidence decreased from 25.9 to 7.4 per 1,000 person-years in 2025, corresponding to a 70.9% reduction (95% CI, 51.9%-82.4%). Temporal analysis demonstrated significant declines of HCV viremia incidence in 2019-2022, followed by a plateau phase in 2023-2025. Our finding supported that nationwide progress toward HCV elimination has contributed to the significant reduction of HCV burden among PWH; however, the plateau phase indicates potential ongoing, residual HCV transmission among PWH with continued risk behaviors.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: